Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir
Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir
复制标题
DOI：
10.1016/j.ijpharm.2017.07.024
复制
发表时间：
2017-08-30
影响因子：
5.8
通讯作者：
Decleves, Xavier
中科院分区：
文献类型：
--
作者：
Gourdon, Betty;Chemin, Caroline;Decleves, Xavier
Targeting intestinal di-and tri-peptide transporter PepT1 with prodrugs is a successful strategy to improve oral drug bioavailability, as demonstrated with valacyclovir, a prodrug of acyclovir. The aim of this new drug delivery strategy is to over-concentrate a poorly absorbed drug on the intestinal membrane surface by targeting PepT1 with functionalized polymer nanoparticles. In the present study, poly(lactic acid)-poly(ethylene glycol)-ligand (PLA-PEG-ligand) nanoparticles were obtained by nanoprecipitation. A factorial experimental design allowed us to identify size-influent parameters and to obtain optimized approximate to 30 nm nanoparticles. Valine, Glycylsarcosine, Valine-Glycine, and Tyrosine-Valine were chemically linked to PLA-PEG. In Caco-2 cell monolayer model, competition between functionalized nanoparticles and [H-3] Glycylsarcosine, a strong substrate of PepT1, reduced [3H] Glycylsarcosine transport from 22 to 46%. Acyclovir was encapsulated with a drug load of approximate to 10% in valine-functionalized nanoparticles, resulting in a 2.7-fold increase in permeability as compared to the free drug. An in vivo pharmacokinetic study in mice compared oral absorption of acyclovir after administration of 25 mg/kg of valacyclovir, free or encapsulated acyclovir in functionalized nanoparticles. Acyclovir encapsulation did not statistically modify AUC or C-max, but increased t(1/2) and MRT 1.3-fold as compared to free acyclovir. This new strategy is promising for poorly absorbed drugs by oral administration. (C) 2017 Elsevier B.V. All rights reserved.
